Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Nasopharyngeal Carcinoma 2Lymphoma, Non-Hodgkin 2Leukemia 2Hematologic Neoplasms 2Plasmacytoma 1Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Head and Neck Neoplasms 1Carcinoma, Hepatocellular 1Advanced Gastric Cancer 1

Interventions

Cyclophosphamide 18Rituximab 10fludarabine 8ibrutinib 6fludarabine phosphate 6Peripheral Blood Stem Cell Transplantation 5Radiotherapy 4Mycophenolic Acid 4Melphalan 4Filgrastim 4Cyclosporine 4Chlorambucil 4Antilymphocyte Serum 4Antigens, CD19 4Valproic Acid 3Sensitivity and Specificity 3Indium 3Immunotherapy, Adoptive 3Busulfan 3Alemtuzumab 3venetoclax 2sargramostim 2obinutuzumab 2navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 2epratuzumab 2Tacrolimus 2Radioimmunodetection 2Psychiatric Rehabilitation 2Pentostatin 2Paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Leukemia, Lymphocytic, Chronic, B-Cell × CF regimen × Clear all
NCT04767308 2021-02-23

Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies

Huazhong University of Science and Technology

Phase EARLY_PHASE1 Unknown
18 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡